Promega Corporation

Rapt Therapeutics, Inc.

Anton Shakhmin

Thomas A Kirkland

Mary P Hall

Joel R Walker

Thomas Machleidt

Keith V Wood

Wenhui Zhou

Poncho Meisenheimer

David Juergen Wustrow

Mikhail Zibinsky

Rachel Friedman Ohana

Jeffrey J Jackson

Grant Masaaki Shibuya

Dennis X Hu

Omar Robles

Paul Robert Leger

Anqi Ma

Andrew A Ng

Adrian O Dukes

Jacob Bradley Schwarz

Hunter Paul Shunatona

Jack Maung

Akinori Okano

Xinping Han

Cyril Bucher

Michelle Yoo Min Ko

Yoo Min Ko

Minna H T Bui

Hannah Haley

Daniel Poon

Vi-Anh Vu

Blanca Gomez

Thomas Kirland

Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods from making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.

Substituted imidazo[1,2-α]pyrazines as luciferase substrates

Disclosed herein are pyrazole pyrimidine compounds that modulate and/or inhibit hematopoietic progenitor kinase 1, as well as methods of making such compounds and therapeutic methods of using same.

Pyrazole pyrimidine compounds and uses thereof

Described are processes for preparing substituted imidazo[1,2-a]pyrazine compounds of formula (I): by reacting a compound of formula (xi): with carbonyldiimidazole to form the compound of formula (I).

Process for preparing substituted imidazo[1,2-&#x3b1;]pyrazines

Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

Cell impermeable coelenterazine analogues

Disclosed herein are pyrozolo-pyrimidin-amino-cycloalkyl compounds, analogs thereof, pharmaceutical compositions comprising thereof and therapeutic uses therefor.

Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses

Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogues, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods of making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates. The substituted imidazo[1,2-a]pyrazine compounds include compounds of formula (I): 

Substituted imidazo[1,2-a]pyrazines as luciferase substrates

Coelenterazine analogues

Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogues, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods from making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.

Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogs, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods for making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.

Described are substituted imidazo[1,2-a]pyrazine compounds of formula (I), which are coelenterazine analogs, methods for making the compounds, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. 

Substituted imidazo[1,2-A]pyrazines tethered to energy acceptors

Described are coelenterazine analogs, methods for making the analogs, kits comprising the analogs, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof

Growing community of inventors

Grover Beach, CA, United States of America

Anton Shakhmin